



# Dysregulation of *NIPBL* leads to impaired *RUNX1* expression and haematopoietic defects

Mara Mazzola<sup>1</sup> | Alex Pezzotta<sup>1</sup> | Grazia Fazio<sup>2</sup> | Alessandra Rigamonti<sup>1</sup> |  
Erica Bresciani<sup>3</sup> | Germano Gaudenzi<sup>4</sup> | Maria Chiara Pelleri<sup>5</sup> | Claudia Saitta<sup>2</sup> |  
Luca Ferrari<sup>6</sup> | Matteo Parma<sup>7</sup> | Monica Fumagalli<sup>7</sup> | Andrea Biondi<sup>2</sup> |  
Giovanni Cazzaniga<sup>2</sup> | Anna Marozzi<sup>1</sup> | Anna Pistocchi<sup>1</sup>

<sup>1</sup>Dipartimento di Biotecnologie Mediche e Medicina Traslationale, Università degli Studi di Milano, Milano, Italy

<sup>2</sup>Centro Ricerca Tettamanti, Fondazione Tettamanti, Università degli Studi di Milano-Bicocca, Monza, Italy

<sup>3</sup>Oncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

<sup>4</sup>Laboratorio Sperimentale di Ricerche di Neuroendocrinologia Geriatrica e Oncologica, Istituto Auxologico Italiano, IRCCS, Cusano Milanino, Italy

<sup>5</sup>Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Unit of Histology, Embryology and Applied Biology, University of Bologna, Bologna, Italy

<sup>6</sup>Dipartimento di Scienze Cliniche e Comunità, Università degli Studi di Milano, Milano, Italy

<sup>7</sup>Clinica Ematologica e Centro Trapianti di Midollo Osseo, Ospedale San Gerardo, Università di Milano-Bicocca, Monza, Italy

## Correspondence

Anna Pistocchi, Dipartimento di Biotecnologie Mediche e Medicina Traslationale, LITA, Via Fratelli Cervi 93, 20090 Segrate, Milano, Italy.  
Email: anna.pistocchi@unimi.it

## Funding information

The work described in this paper was supported by Individual My first AIRC grant (MFAG #18714) and Piano di Sostegno alla Ricerca 2018 Linea 2, Dept. Biotecnologie Mediche e Medicina Traslationale, Università degli Studi di Milano (PSR Linea2 2018) to AP, and AIRC grant IG-21999 to GC.

## Abstract

The transcription factor *RUNX1*, a pivotal regulator of HSCs and haematopoiesis, is a frequent target of chromosomal translocations, point mutations or altered gene/protein dosage. These modifications lead or contribute to the development of myelodysplasia, leukaemia or platelet disorders. A better understanding of how regulatory elements contribute to fine-tune the *RUNX1* expression in haematopoietic tissues could improve our knowledge of the mechanisms responsible for normal haematopoiesis and malignancy insurgence. The cohesin *RAD21* was reported to be a regulator of *RUNX1* expression in the human myeloid HL60 cell line and during primitive haematopoiesis in zebrafish. In our study, we demonstrate that another cohesin, *NIPBL*, exerts positive regulation of *RUNX1* in three different contexts in which *RUNX1* displays important functions: in megakaryocytes derived from healthy donors, in bone marrow samples obtained from adult patients with acute myeloid leukaemia and during zebrafish haematopoiesis. In this model, we demonstrate that alterations in the zebrafish orthologue *nipblb* reduce *runx1* expression with consequent defects in its erythroid and myeloid targets such as *gata1a* and *spi1b* in an opposite way to *rad21*. Thus, also in the absence of *RUNX1* translocation or mutations, additional factors such as defects in the expression of *NIPBL* might induce haematological diseases.

## KEYWORDS

AML, haematopoiesis, *NIPBL*, *RUNX1*, zebrafish

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

## 1 | INTRODUCTION

In all vertebrates, the RUNX family of transcriptional regulators containing the runt domain (RD) comprises three isoforms: RUNX1, RUNX2 and RUNX3 that, together with the non-DNA-binding CBF $\beta$  subunit, regulate many developmental processes.<sup>1,2</sup> The RUNX members specify their functions depending on their cellular and tissue expression: RUNX1 plays a key role in blood development, primarily in the haematopoietic stem cells (HSCs), RUNX2 is mainly involved in bone morphogenesis, and RUNX3 in cell growth of neurons, epithelial cells and T cells. However, the three RUNX proteins could exert biological activities also in other organs<sup>3-5</sup>; for example, RUNX2 and RUNX3 are known to play a role during haematopoiesis together with RUNX1. In addition, all the RUNX genes are transcribed by a distal and a proximal promoter (*P1* and *P2*, respectively) in two main isoforms that differ in the 5'UTR and in the coding sequence of the first exon.<sup>6,7</sup> The *P1* and *P2*RUNX transcripts are differentially expressed in diverse cell types and during specific developmental stages. Indeed, *P1* and *P2*RUNX1 promoters have been reported to have specific activity patterns in the different haematopoietic lineages during development.<sup>8</sup>

RUNX1 function during haematopoiesis is strictly regulated by post-transcriptional and post-translational modifications such as alternative splicing, acetylation, methylation, phosphorylation and ubiquitination.<sup>9</sup> As transcription factor, RUNX1 targets multiple genes, many of which are also pivotal transcriptional regulators involved in the formation of all haematopoietic lineages including the haematopoietic-specific member of E-twenty-six (ETS) family, PU.1.<sup>10,11</sup> Furthermore, the activity of RUNX1 is carried out by its interaction with different proteins fundamental during haematopoiesis such as GATA1, PU.1, CEBPA, PAX5 and ETS1.<sup>10,12-14</sup>

Given the high complexity in RUNX1 expression and function, its deregulation is commonly associated with haematopoietic diseases. Depletion of *Runx1* in mice and zebrafish models leads to severe defects or complete absence of definitive haematopoiesis.<sup>15-18</sup> RUNX1 is frequently involved in chromosomal translocations observed in acute leukaemias, such as ETV6-RUNX1 in t(12;21) and RUNX1-EVI1 in t(3;21),<sup>19</sup> while the formation of the chimeric protein RUNX1-CBF2T1 (AML1-ETO) is associated with the M2 subtype of acute myeloid leukaemia (AML).<sup>20,21</sup> RUNX1 mutations determine the familial platelet disorder with a propensity for AML (AML/FPD) and the minimally differentiated acute myeloid leukaemia (AML/MO).<sup>22</sup> Importantly, regulation of RUNX1 dosage is essential for the maintenance of normal haematopoiesis<sup>23</sup> and several haematopoietic transcription factors are deputed to regulate RUNX1 expression such as Gata2, Ets factors (Fli-1, Elf-1 and Pu.1) and the SCL/Lmo2/Ldb1 complex.<sup>24</sup> In zebrafish, the subunit Rad21 of the cohesin complex has been identified as a regulator of *runx1* through a forward genetic screen,<sup>25</sup> and multiple predicted and in vivo validated binding sites of Rad21 have been shown to be involved in the regulation of the zebrafish *runx1*.<sup>26</sup>

In this work, we demonstrate that NIPBL, another member of the cohesin complex, positively regulates RUNX1 expression in two different contexts in which it exerts important functions: normal cord blood megakaryocytes derived from healthy donors and bone marrow samples derived from adult AML patients. In addition, we generate a zebrafish model in which the *nipblb*-mediated dysregulation of *runx1* expression leads to haematopoietic defects resulting in decreased expression of the erythroid marker *gata1a* and reduction of mature circulating erythrocytes, and increased expression of myeloid precursors positive for the *spi1b* marker. Our data confirm the regulatory loop between RUNX1-GATA1 and PU.1 during haematopoiesis and highlight a new role of NIPBL on top of this route.

## 2 | MATERIALS AND METHODS

### 2.1 | Patients

Diagnostic bone marrow samples from 34 adult patients affected by AML were collected and characterized for specific molecular aberrancies, including translocations t(9;22), t(8;21) and inv(16), in accordance with specific clinical protocol requirements. The analysed patients belong to different French-American-British (FAB) classification systems (FABs), excluding M3; therefore, all patients were negative for translocation t(15;17) (Table 1). Bone marrow of healthy individuals was collected as controls for gene expression assays, upon appropriate informed consent ASG-A-052A approved on 8 May 2012 by Azienda Socio-Sanitaria of Monza (ASST-Monza). Human material and derived data were used in accordance with the Declaration of Helsinki.

### 2.2 | Animals

Zebrafish embryos were raised and maintained according to international (European Union Directive 2010/63/EU) and national (Italian decree no. 26 of 4 March 2014) guidelines on the protection of animals used for scientific purposes. The fish were maintained under standard conditions in the fish facilities of Bioscience Dept, University of Milan, Via Celoria 26-20133 Milan, Italy (Aut. Prot. n. 295/2012-A-20 December 2012). We express the embryonic ages in hours post-fertilization (hpf) and days post-fertilization (dpf). Zebrafish AB strains obtained from the Wilson laboratory (University College London, London, UK) and *Tg(fli1a:EGFP)*<sup>1,27</sup> were maintained at 28°C on a 14-h light/10-h dark cycle. Embryos were collected by natural spawning, staged according to Ref. 28 and raised at 28°C in fish water (Instant Ocean, 0.1% Methylene Blue) in Petri dishes, according to established techniques. To prevent pigmentation, 0.003% 1-phenyl-2-thiourea (PTU, Sigma-Aldrich) was added to the fish water prior to 24 hpf. Before observations and picture acquisitions, embryos were washed, dechorionated and anaesthetized, with 0.016% tricaine (ethyl 3-aminobenzoate methanesulfonate salt; Sigma-Aldrich).

**TABLE 1** Clinical Features of patients' cohort

Age at onset	Karyotype	FAB classification	NPM	FLT3-ITD	t(9;22)	t(8;21)	inv(16)
1	47	46,XX,t(10;11)(p11;p15)[20]	M0	NEG	NEG	NEG	NEG
2	49	46,XY[20]	M0/M1	NEG	NEG	NEG	NEG
3	48	46,XX[20]	M1	NEG	NEG	NEG	NEG
4	72	47,XY,+mar[10]/46,XY[10]	M2	NEG	NEG	NEG	NEG
5	58	46,XX,t(3;5)(q25;q34)[20]	M2	NEG	NEG	NEG	NEG
6	59	46,XY[20]		NEG	POS	NEG	NEG
7	33	46,XY[15]	M1	NEG	POS	NEG	NEG
8	30	46,XY[20]	M5	NEG	POS	nk	NEG
9	58	46,XY,inv(16)(p13q22)[20]	M4	NEG	POS	nk	NEG
10	76	nk	M5	NEG	POS	nk	NEG
11	78	46,XX[27]	M4	NEG	POS	nk	NEG
12	53	46,XY[22]	M4	NEG	POS	nk	NEG
13	64	46,XX[20]	M5	NEG	POS	nk	NEG
14	75	46,XY[26]	M4	NEG	POS	nk	NEG
15	39	46,XY[20]	M1	POS (A)	NEG	NEG	NEG
16	47	46,XX[20]	M5	POS (A)	NEG	NEG	NEG
17	63	46,XY,t(8;14)(q24;q32),add(13q34)[18]/46,XY[9]	nk	POS (D)	NEG	nk	NEG
18	58	46,XY/47,XY,+8[7/10]	nk	POS (QM)	NEG	nk	NEG
19	50	46,XX[20]	M4	POS (A)	NEG	nk	NEG
20	77	46,XY[20]	nk	POS (A)	NEG	nk	NEG
21	54	46,XX,t(9;22)(q34;q11)[14]/46,XX[6]	M4	POS (A)	NEG	POS	NEG
22	60	46,XX[6]	nk	POS	NEG	nk	NEG
23	62	46,XX[25]	M5	POS (A)	NEG ITD/ POS D835/ D836	nk	NEG
24	58	46,XX[20]	nk	POS (A)	NEG	nk	NEG
25	48	46,XX[20]	M4	POS (A)	POS	NEG	NEG
26	51	46,XX[20]	M5	POS (A)	POS	NEG	NEG
27	68	46,XX[20]	M4	POS (A)	POS ITD/ POS D835/ D836	NEG	NEG
28	46	46,XY[20]	M2	POS	POS	NEG	NEG
29	39	46,XX[22]	M1	POS (A)	POS	nk	NEG
30	58	46,XY	M5	POS (A)	POS	nk	NEG
31	35	46,XY,r(18)(?)[16]/47,idem,+8[3]/46,XY[1]	nk	POS (B)	POS	nk	NEG
32	58	46,XY[24]	M1	POS (A)	POS	nk	NEG
33	70	46,XY[20]	M5	POS (A)	POS	nk	NEG
34	12	46,XY[24]	nk	POS (A)	POS	NEG	NEG

### 2.3 | Reverse transcription and real-time quantitative polymerase chain reaction assays (RT-qPCR)

RNA was extracted from human and zebrafish embryos using TRIzol reagents (Life Technologies), following the manufacturer's protocol. For human samples and RT-qPCR experiments, Superscript II enzyme

(Life Technologies) was used for cDNA synthesis. For this set of experiments, a LightCycler 480II (Roche Diagnostics, Basel, Swiss) was used. Probes were selected according to the Software Probe Finder (Roche Diagnostics) and are reported in Table 2. *hGUS* gene was used as reference gene in human patients and cells derived from healthy donors as standard control. For zebrafish samples, DNase I RNase-free (Roche Diagnostics) treatment was performed to avoid possible

**TABLE 2** Human primer sequences and probe numbers used in qPCR experiments

PRIMER	length	sequence	PROBE
hGUS-L	20	CGCCCTGCCTATCTGTATTC	57
hGUS-R	20	TCCCCACAGGGAGTGTGTAG	
hNIPBL-L	19	CTATGCGAACAGCCCAAAA	55
hNIPBL-R	24	TTCACCTTGCTTACTACCACATTT	
hRAD21-L	20	ATTGACCCAGAGCCTGTGAT	62
hRAD21-R	20	GGGGAAGCTCTACAGGTGGT	
HRUNX1-L	18	ACAAACCCACCGCAAGTC	21
HRUNX1-R	23	CATCTAGTTTCTGCCGATGTCTT	
HSPI1-L	20	CTGGAGTTCCCCAATCACAT	25
HSPI1-R	23	TGATTCAGACATGACAAAAGGA	

**TABLE 3** Zebrafish primer sequences used in qPCR experiments

PRIMER	Length	Sequence
zrpl8-L	21	CTCCGTCTTCAAAGACCATGT
zrpl8-R	21	TCCTTCACGATCCCCTTGATG
zP1-runx1-L	20	ATGGCCTCCAACAGCATCTT
zP2-runx1-L	20	GAGCCGAAACTCACGGAGAC
zrunx1 common-R	20	GCAAACCTCGCTCATCTTC
zspi1b-L	19	GCCATTTCATGGACCCAGG
zspi1b-R	19	ACACCGATGTCGGGGCAA
zgata1a-L	26	AACGACATCTTCAATACTACACTTGC
zgata1a-R	18	GGACACCCAACGAGAAGG

genomic contamination and 1 µg of RNA was reverse-transcribed using the "ImProm-II™ Reverse Transcription System" (Promega). RT-qPCRs were carried out in a total volume of 20 µl containing 1X iQ SYBR Green Supermix (Promega), using proper amount of the RT reaction and a mixture of oligo(dT) and random primers according to manufacturer's instructions. RT-qPCRs were performed using the Bio-Rad iCycler iQ Real-Time Detection System (Bio-Rad). For normalization purposes, *rpl8* expression levels were tested in parallel with the gene of interest. Primers are reported in Table 3. Expression levels in the Y-axis were relative to the control.

## 2.4 | In situ hybridization, o-dianisidine and immunofluorescence analyses

Whole-mount in situ hybridization (WISH) experiments were carried out as described by Thisse et al.<sup>29</sup> For quantification of the observed phenotypes, WISH experiments were done at least in 3 independent batches of embryos (minimum 15-20 embryos for each category). Embryos were fixed overnight in 4% paraformaldehyde (PFA, Sigma-Aldrich) in phosphate-buffered saline (PBS) at 4°C, and then dehydrated stepwise to methanol and stored at -20°C. Antisense riboprobes were previously in vitro labelled with modified nucleotides (i.e. digoxigenin, Roche Diagnostics). *runx1*,<sup>30</sup> *spi1b*<sup>31</sup> and *gata1a*<sup>32</sup> probes were synthesized according to literature. To detect haemoglobin activity, o-dianisidine (Sigma)


staining was performed as described in Ref. 33. Controls and MO-injected embryos at the same developmental stage were scored from 1 to 3 according to the intensity of the staining by microscopy, and o-dianisidine-positive cells on the yolk surface and in the Caudal haematopoietic tissue (CHT) were compared.

## 2.5 | Injections

Injections were carried out on one- to two-cell stage embryos. Details of concentration and sequence of *nipblb* morpholino (*nipblb*-MO, Gene Tools, Oregon, US) and *rad21*-MO (Gene Tools) are described in Ref. 34 and Ref. 25, respectively. In all experiments, MO-injected embryos were compared to embryos at the same developmental stage injected with the same amount of a ctrl-MO that has no target in zebrafish (Gene Tools LLC). The *runx1*/PCS2+ construct was kindly provided by C.E. Burns<sup>18</sup> and injected at a concentration of 200 pg/embryo.

## 2.6 | Statistical analyses

For RT-qPCR experiments, data were statistically analysed applying one-way analysis of variance (ANOVA), defining  $P \leq .05$  (\*),  $P \leq .01$  (\*\*) and  $P \leq .001$  (\*\*\*) as statistically significant values.<sup>35</sup> Data were analysed using the comparative  $\Delta\Delta\text{Ct}$  method. Both ANOVA and



**FIGURE 1** Positive correlation between *NIPBL* and *RUNX1* expression in megakaryocytes derived from healthy donors and in bone marrow cells derived from 34 adult AML patients. A and B, Spearman's correlation between *RUNX1* and *RAD21* (A) or *NIPBL* (B) in cord blood megakaryocytes (MK) derived from healthy donors. C and D, Spearman's correlation between *RUNX1* and *RAD21* (C) or *NIPBL* (D) in bone marrow cells (BM) derived from 34 adult AML patients without aberrant *RUNX1* alterations (mutations or translocations). E and F, Spearman's correlation between *RUNX1* and *NIPBL* in 34 adult AML patients without (NPM1wt) (E) or with NPM1 mutation (NPMc+) (F). Spearman's correlation analysis showed a significant positive correlation of the ratio of *RUNX1* expression only versus *NIPBL*, not versus *RAD21*.  $r$  = Spearman's correlation coefficient

standard deviation (SD) values refer to data from triplicate samples. In zebrafish, at least three different experiments were done for each analysis.

The degree of linear relationship between *RAD21*, *NIPBL*, *RUNX1*, *MPL* and *SPI1* expression levels was calculated using Spearman's correlation coefficient ( $r$  value).

## 2.7 | TRAM analysis

TRAM (Transcriptome Mapper) software<sup>36</sup> allows the import, decoding of probe set identifiers to gene symbols via UniGene data parsing,<sup>37</sup> integration and normalization of gene expression data in tab-delimited text format for the generation and analysis of transcriptome maps. We analysed the transcriptome map previously obtained from a gene expression profile datasets for normal human megakaryocytes (MK) cells derived from healthy donors.<sup>38</sup> The dataset is composed of 19 samples previously described (Pool D in Ref. 38). In particular, we used the function "Export" of TRAM software

in order to obtain normalized expression values assigned to *NIPBL*, *RAD21*, *RUNX1* and *MPL* genes for each sample. The degree of linear relationship between *RAD21*, *NIPBL*, *RUNX1*, *MPL* and *SPI1* expression levels was calculated using Spearman's correlation coefficient ( $r$  value).

## 3 | RESULTS

### 3.1 | Positive correlation between *NIPBL* and *RUNX1* expression in normal megakaryocytes derived from healthy donors and bone marrow cells derived from adult AML patients

*RUNX1* expression has been reported to be regulated by the cohesin subunit *RAD21* and the CTCF insulator in human myelocytic leukaemia cells HL-60.<sup>26</sup> As *RUNX1* is pivotal in the differentiation of megakaryocytes and myeloid lineages, we investigated the relative expression of *RAD21* and *RUNX1* in two different contexts in


which *RUNX1* exerts important functions: the differentiation of the megakaryocytes and myeloid compartments under physiological and pathological conditions. For the megakaryocytes compartment in physiological condition, we performed in silico analyses of quantitative transcriptome maps, using TRAM (Transcriptome Mapper) software, which allows import and effective integration of data obtained by different experimenters, experimental platforms and data sources.<sup>36</sup> In megakaryocytes (MK) derived from healthy donors, *RAD21* expression did not correlate with the expression levels of *RUNX1* (Figure 1A). Conversely, we found a positive correlation between the expression of *RUNX1* and that of *NIPBL*, another member of the cohesin complex (Figure 1B). To explore the myeloid compartment under pathological condition, we used bone marrow (BM) cells derived from adult AML patients. Similar to TRAM analyses, when *RAD21* and *RUNX1* expressions were investigated in a cohort of 34 AML adult patients without anomalies in chromosome 21 that contains the *RUNX1* locus, no significant correlation was reported (Figure 1C). Conversely, we observed the positive *NIPBL/RUNX1* correlation already detected in megakaryocytes (Figure 1D).

We previously showed that *NIPBL* transcript abundance is decreased in AML patients carrying the mutated *NUCLEOPHOSMIN1* (*NPM1*), which transfers *NPM1* in the cytoplasm (*NPMc+*), compared to the *NPM1* wild-type (*NPM1wt*).<sup>34</sup> Therefore, we analysed the correlation between the expression of *NIPBL* and *RUNX1* in BM cells derived from 20 patients *NPMc+*, selected among the 34 AML patients, compared to 14 patients *NPM1wt* and found a significant positive correlation in *NPMc+* but not in *NPM1wt* AML patients (Figure 1E-F). Taken together, these findings suggest a new role for *NIPBL*, different from that of *RAD21*, in the regulation of *RUNX1* expression and that aberrant expression of *NIPBL*, such as in AML


patients with *NPM+* mutation, might lead to alteration in *RUNX1* transcript levels.

### 3.2 | Knock-down of *nipblb* specifically reduces *runx1* expression in zebrafish


To confirm the positive correlation between *NIPBL* and *RUNX1* observed in human, we took advantage of a zebrafish model with down-regulation of *nipblb*, the orthologue of the human *NIPBL*, previously generated in our laboratory.<sup>34</sup> The expression of *runx1* was analysed in embryos at 30 and 48 hpf as definitive HSCs arise from the vascular endothelium from these developmental stages. Moreover, we verified that both *P1-P2runx1* isoforms were highly expressed from 24 hpf (Figure S1). WISH analyses showed a reduction of the *runx1* transcript in the aorta-gonad mesonephric (AGM) tissue in *nipblb*-MO-injected embryos compared to controls at the same developmental stage. The injection of the full-length *runx1*/mRNA rescued this phenotype as expected (Figure 2A-C). As the full-length *runx1* riboprobe does not distinguish between the *P1*- and *P2runx1* isoforms present in zebrafish,<sup>8</sup> we performed RT-qPCR analysis of both isoforms, revealing a significant reduction exclusively in *P2runx1* transcript levels following *nipblb* down-regulation. The expression of both isoforms was increased in embryos injected with *nipblb*-MO and *runx1*mRNA, confirming the efficacy of the *runx1* overexpression (Figure 2D-E). These results provide evidence that *nipblb* knock-down causes the reduction of *runx1* in zebrafish, confirming the positive correlation between *NIPBL* and *RUNX1* expression observed in normal megakaryocytes and in BM of AML patients.



**FIGURE 2** *runx1* expression is specifically reduced following *nipblb* down-regulation. A-C WISH analyses of *runx1* expression at the stage of 30 hpf in embryos injected with control morpholino (ctrl-MO) (A), *nipblb*-MO (B) and *nipblb*-MO with *runx1*-mRNA (C). The *runx1* expression in the caudal region (higher magnification in the box) is reduced following *nipblb* down-regulation and rescued in embryos co-injected with *nipblb*-MO and *runx1* mRNA. E-F, RT-qPCR analyses of the *P1runx1* (D) and *P2runx1* (E) isoforms in ctrl-MO-, *nipblb*-MO- and *nipblb*-MO/*runx1*mRNA-injected embryos at 48 hpf. Scale bars indicate 100  $\mu$ m. One-way ANOVA with Bonferroni correction, \*\* $P < .01$ , \* $P < .05$ , n.s.: non-significant



**FIGURE 3** NIPBL-mediated *RUNX1* down-regulation leads to impaired expression of *RUNX1* target genes in both human and zebrafish. A, Spearman's correlation between *RUNX1* and *MPL* in cord blood megakaryocytes (MK) derived from healthy donors. B, Spearman's correlation between *RUNX1* and *SPI1* in bone marrow cells (BM) derived from 34 adult AML patients without aberrant *RUNX1* alterations (mutations or translocations).  $r$  = Spearman's correlation coefficient. C and D, RT-qPCR analyses of 48 hpf ctrl-, *nipblb*- and *nipblb*-MO/*runx1*mRNA-injected embryos. C, The expression of the erythroid marker *gata1a* was decreased following *nipblb*-MO injection in comparison with controls and rescued in *nipblb*-MO/*runx1*mRNA-injected embryos. D, The expression of the myeloid marker *spi1b* was increased in both *nipblb*-MO- and *nipblb*-MO/*runx1*mRNA-injected embryos in comparison with controls. E-G, *O*-dianisidine staining showed a reduction of mature circulating erythrocytes in *nipblb*-MO-injected embryos at 48 hpf in comparison with ctrl-MO. Co-injection with the full-length *runx1* mRNA rescues the *o*-dianisidine reduction. Lateral views anterior to the left (upper panels) and ventral views of the anterior region (lower panels). H-J, WISH analyses showed an increased expression of *spi1b* in *nipblb*-MO- and *nipblb*-MO/*runx1*mRNA-injected embryos in comparison with ctrl-MO. Scale bars indicate 100  $\mu\text{m}$  in (E-G) and 200  $\mu\text{m}$  in (H-J). One-way ANOVA with Bonferroni correction, \*\*\* $P < .001$ , \*\* $P < .01$ , \* $P < .05$ , n.s.: non-significant



**FIGURE 4** The down-regulation of *rad21* in zebrafish enhances the expression of *runx1* and its downstream targets *gata1a* and *spi1b*. A-D, RT-qPCR analyses of 48 hpf ctrl- and *rad21*-MO-injected embryos. The expression of both *P1* (A) and *P2runx1* (B) isoforms and of *runx1* targets *gata1a* (C) and *spi1b* (D) was increased following *rad21*-MO injection in comparison to controls at 48 hpf. One-way ANOVA with Bonferroni correction, \*\*\* $P < .001$ , \*\* $P < .01$ , \* $P < .05$ , n.s: non-significant

### 3.3 | NIPBL-mediated RUNX1 down-regulation impairs the expression of RUNX1 target genes

We further verified whether the NIPBL-mediated RUNX1 reduction affects the expression of RUNX1 haematopoietic downstream targets. In MK cells derived from healthy donors, we observed a positive correlation between the expression of RUNX1 and that of *MPL* gene, the marker of megakaryocyte/platelet differentiation (Figure 3A).<sup>39</sup> In BM cells derived from AML human patients, we showed a positive correlation between the expression of RUNX1 and its targets *SPI1*, the marker of myeloid precursors (Figure 3B).<sup>40</sup> The expression of *runx1* targets *gata1a* and *spi1b* was investigated also in zebrafish in *nipblb*-MO-injected embryos and controls at 48 hpf. The expression of *gata1a*, analysed by RT-qPCR, was significantly decreased following *nipblb* down-regulation as a result of *runx1* reduction. Indeed, the injection of the *runx1*mRNA in the *nipblb*-MO-injected embryos rescued the *gata1a* expression (Figure 3C). Conversely, the expression of *spi1b* was significantly increased in both *nipblb*-MO- and *nipblb*-MO/*runx1*mRNA-injected embryos (Figure 3D). Consistent with the role of *runx1* in the positive regulation of the erythroid lineage, mature circulating erythrocytes, visualized by *o*-dianisidine staining at 48 hpf, were drastically reduced in *nipblb*-MO-injected embryos (70%;  $N = 140$ ), compared to controls (Figure 3E-F). This phenotype is not caused by alterations in vascular tree development as shown in the *Tg(fli1a:EGFP)*<sup>1</sup> embryos (Figure S2), or absence of

blood flow (data not shown). The reduction of *o*-dianisidine-positive erythrocytes was rescued in the 75% of the *nipblb*-MO-*runx1*mRNA-injected embryos ( $N = 113$ ) (Figure 3G), confirming that the phenotype is dependent on *nipblb*-mediated *runx1* reduction.

WISH analyses of *spi1b* expression showed the increase of the transcript in the CHT of *nipblb*-MO-injected embryos (Figure 3H-I) confirming the RT-qPCR data and our previous findings.<sup>34</sup> In agreement with the positive regulation exerted by *runx1* on *spi1b*, the injection of the *runx1*/mRNA further enhanced this phenotype (Figure 3J).<sup>40</sup>

As it has been previously demonstrated that *rad21*, another member of the cohesin complex, regulates *runx1* in zebrafish embryos during primitive haematopoiesis,<sup>25,26</sup> we further verified the expression of *runx1* during definitive haematopoiesis following *rad21* down-regulation by means of morpholino injection.<sup>25</sup> *rad21*-MO-injected embryos at 48 hpf showed an increased expression of both *P1* and *P2runx1* isoforms and a consequent increase in the expression of the *runx1* downstream targets *gata1a* and *spi1b* (Figure 4A-D). These data are in agreement with the negative regulation exerted by RAD21 on RUNX1 expression reported in the myeloid HL60 cell line.<sup>26</sup>

## 4 | DISCUSSION

The transcription factor RUNX1 is a pivotal gene in the development and differentiation of HSCs: as transcription factor, it controls the expression of master genes involved in megakaryocytes and myeloid lineages differentiation, and it interacts with different proteins fundamental during haematopoiesis. Somatic translocations and mutations of RUNX1 are causative of haematological diseases such as myelodysplastic syndrome, acute myeloid leukaemia, acute lymphoblastic leukaemia, chronic myelomonocytic leukaemia and acute megakaryoblastic leukaemia with familial platelet disorder. In addition, dysregulation of RUNX1 expression might lead to impaired haematopoiesis and the insurgence of a pathological condition. Among the genes discovered to regulate RUNX1, there is RAD21, a member of the cohesin complex, and the CTCF insulator.<sup>26</sup> In human K562 cells and murine and zebrafish models, RAD21 and CTCF bind to a cis-regulatory element (CRE) enhancer located in an intron between the *P1* and *P2RUNX1* promoters, associated with RNApolIII.<sup>41</sup> As cohesins preferentially bind to transcriptionally active genes and recruit RNApolIII and chromatin modifiers to activate gene transcription,<sup>42</sup> it would have been expected that RAD21 positively regulates RUNX1 transcription by binding to the CRE between *P1* and *P2* promoters. This finding is reported by Supernat and colleagues<sup>43</sup> in patients with endometrial cancers. However, in a zebrafish mutant for Rad21 the expression of *runx1* was reduced<sup>25</sup> and the *P1* and *P2runx1* isoforms were differently expressed: *P1* isoform was increased, while *P2* was not varied or even decreased following Rad21 depletion.<sup>26</sup> Moreover, the silencing of RAD21 in the human HL60 leukaemic cell line leads to an enhanced expression of RUNX1 indicating that RAD21 might also repress RUNX1 expression.<sup>26</sup> In our study, we did not observe

a significant correlation between the expression of *RAD21* and *RUNX1* neither in megakaryocytes derived from healthy donors, nor in bone marrow cells derived from a selected cohort of adult AML patients. However, we showed that during definitive haematopoiesis, the down-regulation of *rad21* in zebrafish enhances the expression of both *P1* and *P2runx1* isoforms leading to impaired expression of the *runx1* downstream targets *gata1a* and *spi1b*.

The different members of the cohesin complex can exert similar or individual functions in the regulation of gene expression. For example, Zuin et al<sup>44</sup> demonstrated that *NIPBL* binds to chromatin independently in time and space than other cohesins, revealing a new role for *NIPBL* as transcriptional regulator not linked to the cohesin complex. In this work, we demonstrate that *NIPBL* exerts a different regulation on *RUNX1* expression than *RAD21*. Indeed, in three different contexts: normal megakaryocytes derived from healthy donors, bone marrow cells derived from adult AML patients and zebrafish embryos with *nipblb* down-regulation, we demonstrate a positive correlation between *NIPBL* and *RUNX1* expression.

The *NIPBL*-mediated *RUNX1* dysregulation affects the *RUNX1* downstream targets responsible for the differentiation of the erythroid and myeloid lineages. *RUNX1* augmented *GATA1*-mediated promoter activation; in this regard, the decrease in *RUNX1* transcription/activity leads to down-regulation of the erythroid *GATA1* transcription factor.<sup>45</sup> Interestingly, cohesins-haploinsufficient cells presented enriched or depleted *GATA1* consensus binding sites indicating that they can modulate *GATA1* activity directly or through other molecules.<sup>12,46</sup>

Also the *SPI* expression is positively regulated by *RUNX1*, facilitating the interaction between the *SPI* enhancer and its proximal promoter.<sup>47</sup> Indeed, we observed a positive correlation between *RUNX1* and *SPI1* in human samples and in zebrafish when we forced *runx1* expression. However, following *nipblb* down-regulation, we also observed an increase in *spi1b* expression according to our previous data.<sup>34</sup> This result does not correlate with the *runx1* reduction and its positive activity on *spi1b* expression and raises three possibilities: first that the increased number of myeloid precursors, previously reported in zebrafish following *nipblb*-MO injection,<sup>34</sup> leads to an augmented number of cells expressing *spi1b* with a consequent total increase of *spi1b* transcript. Second, it has been reported that the chromatin structure at the *spi1b*/*PU.1* locus could be differentially regulated during the different stages of haematopoiesis,<sup>11</sup> suggesting the possibility that other mechanisms than *RUNX1* might control *spi1b* expression. For example, we demonstrated that the canonical Wnt pathway, modulated by *nipblb*, has a pivotal role in regulating *spi1b* myeloid expression during definitive haematopoiesis in zebrafish.<sup>34</sup> Moreover, in vitro and in vivo studies demonstrated that forced expression of *gata1* down-regulates *spi1b*, while forced expression of *spi1b* down-regulates *gata1*.<sup>48-50</sup> In this scenario, the *nipblb*-mediated *runx1* down-regulation might lead to *spi1b* enforced expression that, in turn, reduces *gata1a* expression. Alternatively, the two *P1* and *P2runx1* isoforms might exert different functions on *spi1b* regulation. Indeed, as for the case of *Rad21* zebrafish mutants,<sup>26</sup> we demonstrated that the down-regulation of

*nipblb* differently affects the two isoforms by significantly reducing only the *P2runx1*. Third, it has been demonstrated that *NIPBL* might regulate *SPI1* by itself, encompassing the *Runx1* regulation.<sup>44</sup>

Although in this work we did not address the mechanism through which *NIPBL* regulates *RUNX1* expression, we demonstrated that *NIPBL* positively regulates *RUNX1* transcription and that the link between *NIPBL* dysregulation and *RUNX1*-driven haematopoietic defects might explain haematological malignancy occurrence. Thus, also in the absence of *RUNX1* translocation or mutations, additional factors such as defects in the expression of *NIPBL* observed in AML patients might contribute to haematological diseases.

## ACKNOWLEDGMENTS

The authors thank Carol Burns for the *runx1* mRNA. They also thank Dorela Meta and Giulia Salmoiraghi for technical help in data preparation.

## CONFLICT OF INTEREST

The authors declare no competing financial interest.

## AUTHOR CONTRIBUTION

MM, GF, CS, AR, AP, MCP, GG and LF contributed to the study. MP and MF provided patients samples. EB, AP, GC, AB, and AM designed and performed the experiments and analysed the data. AP designed and organized the experiments and analysed the data; and wrote the manuscript.

## DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

## ORCID

Alex Pezzotta  <https://orcid.org/0000-0003-1788-5880>

Grazia Fazio  <https://orcid.org/0000-0001-7077-8422>

Alessandra Rigamonti  <https://orcid.org/0000-0002-1938-2278>

Germano Gaudenzi  <https://orcid.org/0000-0003-3516-8471>

Maria Chiara Pelleri  <https://orcid.org/0000-0002-7925-186X>

Claudia Saitta  <https://orcid.org/0000-0002-5842-7774>

Luca Ferrari  <https://orcid.org/0000-0003-0103-2170>

Giovanni Cazzaniga  <https://orcid.org/0000-0003-2955-4528>

Anna Marozzi  <https://orcid.org/0000-0001-9007-2590>

Anna Pistocchi  <https://orcid.org/0000-0001-9467-2542>

## REFERENCES

- Westendorf JJ, Hiebert SW. Mammalian runt-domain proteins and their roles in hematopoiesis, osteogenesis, and leukemia. *J Cell Biochem*. 1999;32-33:51-58.
- Canon J, Banerjee U. Runt and Lozenge function in Drosophila development. *Semin Cell Dev Biol*. 2000;11(5):327-336.
- Blyth K, Vaillant F, Jenkins A, et al. Runx2 in normal tissues and cancer cells: a developing story. *Blood Cells Mol Dis*. 2010;45(2):117-123.
- Liakhovitskaia A, Lana-Elola E, Stamateris E, et al. The essential requirement for Runx1 in the development of the sternum. *Dev Biol*. 2010;340(2):539-546.

5. Lotem J, Levanon D, Negreanu V, et al. Runx3 at the interface of immunity, inflammation and cancer. *Biochim Biophys Acta - Rev Cancer*. 2015;1855(2):131-143.
6. Miyoshi H, Ohira M, Shimizu K, et al. Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. *Nucleic Acids Res*. 1995;23(14):2762-2769.
7. Ghozi MC, Bernstein Y, Negreanu V, et al. Expression of the human acute myeloid leukemia gene AML1 is regulated by two promoter regions. *Proc Natl Acad Sci USA*. 1996;93(5):1935-1940.
8. Lam EYN, Chau JYM, Kalev-Zylinska ML, et al. Zebrafish runx1 promoter-EGFP transgenics mark discrete sites of definitive blood progenitors. *Blood*. 2009;113(6):1241-1249.
9. Goyama S, Huang G, Kurokawa M, et al. Posttranslational modifications of RUNX1 as potential anticancer targets. *Oncogene*. 2015;34(27):3483-3492.
10. Huang G, Zhang P, Hirai H, et al. PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. *Nat Genet*. 2008;40(1):51-60.
11. Hoogenkamp M, Krysinska H, Ingram R, et al. The Pu.1 locus is differentially regulated at the level of chromatin structure and noncoding transcription by alternate mechanisms at distinct developmental stages of hematopoiesis. *Mol Cell Biol*. 2007;27(21):7425-7438.
12. Elagib KE, Racke FK, Moggas M, et al. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. *Blood*. 2003;101(11):4333-4341.
13. Kim W-Y. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. *EMBO J*. 1999;18(6):1609-1620.
14. Tagoh H, Ingram R, Wilson N, et al. The mechanism of repression of the myeloid-specific c-fms gene by Pax5 during B lineage restriction. *EMBO J*. 2006;25(5):1070-1080.
15. Okuda T, Van Deursen J, Hiebert SW, et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. *Cell*. 1996;84(2):321-330.
16. Wang Q, Stacy T, Binder M, et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. *Proc Natl Acad Sci USA*. 1996;93(8):3444-3449.
17. Kalev-Zylinska ML, Horsfield JA, Flores MVC, et al. Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX-1-CBF2T1 transgene advances a model for studies of leukemogenesis. *Development*. 2002;129(8):2015-2030.
18. Burns CE, Traver D, Mayhall E, et al. Hematopoietic stem cell fate is established by the Notch-Runx pathway. *Genes Dev*. 2005;19(19):2331-2342.
19. Lutterbach B, Hiebert SW. Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. *Gene*. 2000;245(2):223-235.
20. Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. *Blood*. 1992;80(7):1825-1831.
21. Kozu T, Miyoshi H, Shimizu K, et al. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. *Blood*. 1993;82(4):1270-1276.
22. Jongmans MCJ, Kuiper RP, Carmichael CL, et al. Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: Clues for improved identification of the FPD/AML syndrome. *Leukemia*. 2010;24(1):242-246.
23. Yamagata T, Maki K, Mitani K. Runx1/AML1 in normal and abnormal hematopoiesis. *Int J Hematol*. 2005;82(1):1-8.
24. Tober J, Maijenburg MW, Speck NA. Taking the leap: Runx1 in the formation of blood from endothelium. *Curr Top Dev Biol*. 2016;118:113-162.
25. Horsfield JA, Anagnostou SH, Hu JKH, et al. Cohesin-dependent regulation of Runx genes. *Development*. 2007;134(14):2639-2649.
26. Marsman J, O'Neill AC, Kao BRY, et al. Cohesin and CTCF differentially regulate spatiotemporal runx1 expression during zebrafish development. *Biochim Biophys Acta - Gene Regul Mech*. 2014;1839(1):50-61.
27. Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. *Dev Biol*. 2002;248(2):307-318.
28. Kimmel C, Ballard W, Kimmel S, et al. Stages of embryonic development of the zebrafish. *De Dyn*. 1995;203:253-310.
29. Thisse C, Thisse B. High-resolution in situ hybridization to whole-mount zebrafish embryos. *Nat Protoc*. 2008;3:59-69.
30. Burns CE, DeBlasio T, Zhou Y, et al. Isolation and characterization of runxa and runxb, zebrafish members of the runt family of transcriptional regulators. *Exp Hematol*. 2002;30(12):1381-1389.
31. Hsu K, Traver D, Kutok JL, et al. The pu.1 promoter drives myeloid gene expression in zebrafish. *Blood*. 2004;104:1291-1297.
32. Hammerschmidt M, Pelegri F, Mullins MC, et al. dino and mercedes, two genes regulating dorsal development in the zebrafish embryo. *Development*. 1996;123:95-102.
33. Rhodes J, Hagen A, Hsu K, et al. Interplay of pu.1 and Gata1 determines myelo-erythroid progenitor cell fate in zebrafish. *Dev Cell*. 2005;8(1):97-108.
34. Mazzola M, Deflorian G, Pezzotta A, et al. NIPBL: a new player in myeloid cell differentiation. *Haematologica*. 2019;104:1332-1341.
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*. 2001;25:402-408.
36. Lenzi L, Facchin F, Piva F, et al. TRAM (Transcriptome Mapper): Database-driven creation and analysis of transcriptome maps from multiple sources. *BMC Genom*. 2011;12(1): <https://doi.org/10.1186/1471-2164-12-121>
37. Lenzi L, Frabetti F, Facchin F, et al. UniGene tabulator: A full parser for the UniGene format. *Bioinformatics*. 2006;22(20):2570-2571.
38. Pelleri MC, Piovesan A, Caracausi M, et al. Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS). *BMC Med Genomics*. 2014;7(1): <https://doi.org/10.1186/s12920-014-0063-z>
39. Songdej N, Rao AK. Hematopoietic transcription factor mutations: Important players in inherited platelet defects. *Blood*. 2017;129(21):2873-2881.
40. Imperato MR, Cauchy P, Obier N, et al. The RUNX1-PU.1 axis in the control of hematopoiesis. *Int J Hematol*. 2015;101(4):319-329.
41. Leeke B, Marsman J, O'Sullivan JM, et al. Cohesin mutations in myeloid malignancies: Underlying mechanisms. *Exp Hematol Oncol*. 2014;3(1):13.
42. Dorsett D, Merckenschlager M. Cohesin at active genes: a unifying theme for cohesin and gene expression from model organisms to humans. *Curr Opin Cell Biol*. 2013;25(3):327-333.
43. Supernat A, Łapińska-Szumczyk S, Sawicki S, et al. Dereglulation of RAD21 and RUNX1 expression in endometrial cancer. *Oncol Lett*. 2012;4(4):727-732.
44. Zuin J, Franke V, van IJcken WFJ, et al. A cohesin-independent role for NIPBL at promoters provides insights in CdLS. *PLoS Genet*. 2014;10(2):e1004153.
45. Mullenders J, Aranda-Orgilles B, Lhoumaud P, et al. Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms. *J Exp Med*. 2015;212(11):1833-1850.
46. Mazumdar C, Shen Y, Xavy S, et al. Leukemia-associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation. *Cell Stem Cell*. 2015;17:675-688.

47. Staber PB, Zhang P, Ye M, et al. The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells. *Blood*. 2014;124(15):2391-2399.
48. Kulesa H, Frampton J, Graf T. GATA-1 reprograms avian myelomonocytic cell lines into eosinophils, thromboblats, and erythroblats. *Genes Dev*. 1995;9(10):1250-1262.
49. Nerlov C, Graf T. PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. *Genes Dev*. 1998;12(15):2403-2412. <https://doi.org/10.1101/gad.12.15.2403>.
50. Jin H, Li L, Xu J, et al. Runx1 regulates embryonic myeloid fate choice in zebrafish through a negative feedback loop inhibiting Pu.1 expression. *Blood*. 2012;119(22):5239-5249.

#### SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Mazzola M, Pezzotta A, Fazio G, et al. Dysregulation of *NIPBL* leads to impaired *RUNX1* expression and haematopoietic defects. *J Cell Mol Med*. 2020;24:6272–6282. <https://doi.org/10.1111/jcmm.15269>